BAYER AG

The FDA accepted Bayer's New Drug Application for elinzanetant, targeting moderate-to-severe vasomotor symptoms in menopause. Supported by OASIS 1, 2, and 3 trials, elinzanetant showed reduced VMS frequency and severity, improved sleep, and quality of life, with a favorable safety profile. OASIS 4 is ongoing.

Bayer's NDA for elinzanetant, a non-hormonal treatment for menopause-related VMS, accepted by FDA. Based on Phase III OASIS studies, it shows promise in treating moderate-to-severe VMS and sleep disturbances. Bayer aims to expand treatment options for menopause, impacting women's healthcare globally.

Syneos Health appoints Costa Panagos as CEO, succeeding Colin Shannon who becomes Executive Chairman. Panagos, with 25+ years in CRO leadership, aims to build on Syneos Health's momentum and deliver differentiated offerings from early development to commercialization.

FDA accepts Bayer's NDA for elinzanetant, a dual NK-1 and 3 receptor antagonist for treating moderate to severe VMS in menopause, based on positive OASIS Phase III study results.

The agricultural biotechnology market is projected to grow from $55.24 billion in 2023 to $89.52 billion by 2028, driven by increased food demand, technological innovations, and sustainable practices. Key players like BASF SE and Bayer AG focus on integrated solutions to enhance productivity and sustainability.

Bayer announced FDA acceptance of its NDA for elinzanetant, a non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause. The NDA is supported by positive results from Phase III studies OASIS 1, 2, and 3. Elinzanetant, a dual neurokinin-1 and 3 receptor antagonist, aims to offer a new treatment option for menopausal women.

Bayer's NDA for elinzanetant, a non-hormonal treatment for menopause-related VMS, was accepted by the FDA. Based on positive Phase III OASIS studies, it's the first dual NK-1 and 3 receptor antagonist. Elinzanetant targets VMS by modulating KNDy neurons, potentially improving sleep disturbances. Bayer aims to expand treatment options for menopause symptoms globally.

AI in drug development can reduce costs and improve clinical trial success, but challenges like data quality and regulatory acceptance remain.

Lance Yuen, new CEO of CK Life Sciences, aims to leverage his experience at Bristol-Myers Squibb and Bayer to commercialize drug candidates and boost earnings. Yuen, a 'commercialization expert,' believes in early involvement in drug development. CK Life recently merged its Wex Pharmaceuticals with Virios Therapeutics for $100 million.